SFA Therapeutics
Manufacturing · Pennsylvania, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
610 York Rd Ste 400, Jenkintown, Pennsyl...Website
www.sfatherapeutics.comRevenue
<$5 MillionIndustry
About SFA Therapeutics
SFA Therapeutics is focused on developing a next-generation oral immune tolerance therapy, SFA-002, for psoriasis, which aims to restore immune function without broadly suppressing the immune system. The investigational therapy is designed for once-daily dosing and has shown promising results in early human trials, demonstrating significant clearance in plaque psoriasis. The company utilizes a proprietary deuteration platform to create new chemical entities from naturally occurring short-chain fatty acids, with plans to expand its pipeline to include treatments for pancreatic cancer, liver cancer, and other autoimmune diseases. SFA Therapeutics targets patients suffering from chronic inflammatory diseases, particularly those with mild to severe plaque psoriasis.Explore more
SFA Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to SFA Therapeutics
Compare insights from companies similar to SFA Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
SFA Therapeutics
<$5M
1-10
Private
<$5M
2017
JK
James KirwinChief Operating Officer & Senior VP, Clinical Development
SFA Therapeutics Tech Stack
A closer look at the technologies used by SFA Therapeutics
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SFA Therapeutics
Sign Up For FreeTo access detailed company insights
SFA Therapeutics is focused on developing a next-generation oral immune tolerance therapy, SFA-002, for psoriasis, which aims to restore immune function without broadly suppressing the immune system. The investigational therapy is designed for once-daily dosing and has shown promising results in early human trials, demonstrating significant clearan... Read More
